Geode Capital Management
PCSA icon

Geode Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Geode Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.8K Buy
24,908
+9,585
+63% +$26.2K ﹤0.01% 4260
2025
Q4 		$44.1K Buy
15,323
+3,191
+26% +$22.3K ﹤0.01% 4258
2025
Q3 		$58.2K Buy
12,132
+10,109
+500% +$53.4K ﹤0.01% 4257
2025
Q2 		$10.4K Buy
2,023
+646
+47% +$4.31K ﹤0.01% 4417
2025
Q1 		$12.7K Buy
1,377
+498
+57% +$7.5K ﹤0.01% 4416
2024
Q4 		$19.6K Buy
879
+91
+12% +$2.57K ﹤0.01% 4386
2024
Q3 		$27K Buy
788
+99
+14% +$3.88K ﹤0.01% 4363
2024
Q2 		$38.8K Buy
+689
New +$33.9K ﹤0.01% 4330
2024
Q1 		– Sell
-244
Closed -$40.8K – 4629
2023
Q4 		$40.8K Sell
244
-61
-20% -$13.6K ﹤0.01% 4400
2023
Q3 		$38.9K Buy
305
+167
+121% +$31.6K ﹤0.01% 4479
2023
Q2 		$34.2K Hold
138
– – ﹤0.01% 4585
2023
Q1 		$36.5K Hold
138
– – ﹤0.01% 4588
2022
Q4 		$75K Buy
138
+8
+6% +$7.73K ﹤0.01% 4491
2022
Q3 		$146K Hold
130
– – ﹤0.01% 4375
2022
Q2 		$182K Hold
130
– – ﹤0.01% 4325
2022
Q1 		$195K Hold
130
– – ﹤0.01% 4397
2021
Q4 		$318K Hold
130
– – ﹤0.01% 4276
2021
Q3 		$556K Buy
130
+55
+73% +$188K ﹤0.01% 3985
2021
Q2 		$306K Buy
75
+19
+34% +$73.4K ﹤0.01% 4158
2021
Q1 		$303K Buy
+56
New +$261K ﹤0.01% 3987

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management's PCSA Position: Q1 2026 in Review

Geode Capital Management increased its Processa Pharmaceuticals (PCSA) stake by 63% in Q1 2026, buying an estimated $26.2K and bringing the position to 24,908 shares worth $62.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4260.

Geode Capital Management first reported a position in PCSA in Q1 2021 and has held it in 20 quarters since. The position peaked at $556K in Q3 2021. 10 funds tracked by Wall St. Rank hold PCSA as of Q1 2026.

  • Geode Capital Management held 24,908 shares of Processa Pharmaceuticals worth $62.8K as of Q1 2026.
  • Geode Capital Management bought 9,585 Processa Pharmaceuticals shares in Q1 2026, an estimated $26.2K.
  • Processa Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4260 holding.
  • Geode Capital Management first reported a position in Processa Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • Geode Capital Management's Processa Pharmaceuticals position peaked at $556K in Q3 2021.
  • 10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.